FindTrial
Sign In

The pharmacogenetics of psoriasis patients

The pharmacogenetics of psoriasis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017764
Enrollment
Unknown
Registered
2018-08-13
Start date
2018-08-10
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Group 2:methotrexate treatment
Group 1:Acitretin

Sponsors

Department of Dermatology, Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. clinical confirmed as moderate or severe vulgaris psoriasis; 2. aged 14 to 70 years male and female.

Exclusion criteria

Exclusion criteria: 1. already given psoriasis drugs in 4 weeks before study; 2. abnormal hepatic or renal function, other laboratory test was not eligible; 3. accompany with other disease or severe complications, given multiple drugs; 4. mental disorder, can't cooperate; 5. pregnant or lactation.

Design outcomes

Primary

MeasureTime frame
Psoriasis area and severity index;—

Countries

China

Contacts

Public ContactWu zhu

Department of Dermatology, Xiangya Hospital, Central South University

zhuwu70@hotmail.com+86 13319509308

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026